65,437 trials
Glioblastoma Multiforme
Primary: Percentage of Participants With Progression Free Survival at 6 Months (PFS-6) — 53.6 percentage of participants
Vision, Low
Primary: Quality of Life Improvement After Three Months of Device Use — 0.84 Logits
Dry Eye Syndromes
Primary: Change From Baseline in Conjunctival Redness Score in the Study Eye Using a 5-Point Scale — 1.9; 2.2; 2.0; 2.1 score on a scale
30% Oxygen Concentration During Colorectal Surgery · 80% Oxygen Concentration During Colorectal Surgery
Primary: Number of Participants With One or More Composite Complications — 314; 314 Participants — p=0.85
Gitelman Syndrome
Primary: Chloriuretic Response to a Thiaizde — 1.23 fractional chloride excretion
Prostatic Hyperplasia
Primary: Change From Baseline in International Prostate Symptom Score (IPSS) by Last Observation Carried Forward (LOCF) Approach at 24 Months — -4.07; -3.28; -3.73; -3.36 Score…
Breast Cancer
Primary: Percentage of Acceptable Overall Image Quality — 30; 33; 3; 0 Participants
ED Patients With Chronic Medical Illnesses
Primary: Change in Physical Function Between Baseline and 60 Days Post-ED Visit — -1.47; -0.83 T-score — p=0.49
AL Amyloidosis
Primary: Number of Participants With Cardiac Response and Non-Response — 26; 30; 40; 33 Participants — p=0.3190
Factor VIII Deficiency, Congenital · Factor 8 Deficiency, Congenital · Autosomal Hemophilia A
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 15; 0 Participants
Hyperlipidemia
Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 Participants
Solid Tumors
Primary: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Atopic Dermatitis
Primary: Percent Change From Baseline in EASI Score in Cohort 3 — -34.24; -34.29; -34.04; -31.03 percent change from baseline in EASI — p=0.5016
Alopecia
Primary: Change From Baseline in Target Area Hair Count (TAHC) at Week 24 — 6.7; 7.1 terminal hairs/cm^2 — p=0.9239
Hairy Cell Leukemia
Primary: Number of Patients Who Obtain Partial Response/Complete Remission — 1; 5 Participants